Department of Cardiology, Center for Coronary Heart Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Special Demand Medical Care Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Thromb Haemost. 2024 Jul;124(7):684-694. doi: 10.1055/s-0043-1771188. Epub 2023 Jul 24.
Lipoprotein(a), or Lp(a), has been recognized as a strong risk factor for atherosclerotic cardiovascular disease. However, the relationship between Lp(a) and bleeding remains indistinct, especially in the secondary prevention population of coronary artery disease (CAD). This investigation aimed to evaluate the association of Lp(a) with long-term bleeding among patients with CAD.
Based on a prospective multicenter cohort of patients with CAD consecutively enrolled from January 2015 to May 2019 in China, the current analysis included 16,150 participants. Thus, according to Lp(a) quintiles, all subjects were divided into five groups. The primary endpoint was bleeding at 2-year follow-up, and the secondary endpoint was major bleeding at 2-year follow-up.
A total of 2,747 (17.0%) bleeding and 525 (3.3%) major bleeding were recorded during a median follow-up of 2.0 years. Kaplan-Meier survival analysis showed the highest bleeding incidence in Lp(a) quintile 1, compared with patients in Lp(a) quintiles 2 to 5 ( < 0.001), while the incidence of major bleeding seemed similar between the two groups. Moreover, restricted cubic spline analysis suggested that there was an L-shaped association between Lp(a) and 2-year bleeding after adjustment for potential confounding factors, whereas there was no significant association between Lp(a) and 2-year major bleeding.
There was an inverse and L-shaped association of Lp(a) with bleeding at 2-year follow-up in patients with CAD. More attention and effort should be made to increase the clinician awareness of Lp(a)'s role, as a novel marker for bleeding risk to better guide shared-decision making in clinical practice.
脂蛋白(a)(Lp(a))已被认为是动脉粥样硬化性心血管疾病的一个强有力的危险因素。然而,Lp(a)与出血之间的关系仍不明确,尤其是在冠心病(CAD)的二级预防人群中。本研究旨在评估 Lp(a)与 CAD 患者长期出血的关系。
基于 2015 年 1 月至 2019 年 5 月中国连续纳入的 CAD 患者前瞻性多中心队列,本分析共纳入 16150 名参与者。因此,根据 Lp(a)五分位,所有患者被分为五组。主要终点为 2 年随访时出血,次要终点为 2 年随访时主要出血。
在中位随访 2.0 年期间,共记录到 2747 例(17.0%)出血和 525 例(3.3%)主要出血。Kaplan-Meier 生存分析显示,Lp(a)五分位 1 的出血发生率最高,与 Lp(a)五分位 2 至 5 的患者相比(<0.001),而两组之间主要出血的发生率似乎相似。此外,调整潜在混杂因素后,限制性立方样条分析提示 Lp(a)与 2 年出血之间呈反向 L 型关联,而 Lp(a)与 2 年主要出血之间无显著关联。
在 CAD 患者中,Lp(a)与 2 年随访时的出血呈负相关和 L 型关联。应更加关注并努力提高临床医生对 Lp(a)作为出血风险新型标志物的认识,以更好地指导临床实践中的决策。